Polar Capital Holdings PLC Seagen Inc. Transaction History

Polar Capital Holdings PLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Dec 13, 2023	SELL	$187.64 - $206.25 $11.3 Million - $12.5 Million	-60,392 Reduced 10.99%	489,000 $94.1 Million
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $11.3 Million - $12.5 Million	-60,392 Reduced 10.99%	489,000 $94.1 Million
Q1 2023 Dec 13, 2023	BUY	$127.59 - $203.08 $70.1 Million - $112 Million	549,392 New	549,392 $111 Million
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $35.2 Million - $56.1 Million	-276,240 Reduced 33.46%	549,392 $111 Million
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $19.3 Million - $22.9 Million	164,836 Added 24.95%	825,632 $106 Million

Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $10.1 Million - $13.5 Million	74,705 Added 12.75%	660,796 $90.4 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $506,728 - $835,139	-4,657 Reduced 0.79%	586,091 $104 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $6.46 Million - $8.52 Million	54,000 Added 10.06%	590,748 $85.1 Million
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $10.6 Million - $14.1 Million	74,000 Added 15.99%	536,748 $83 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $12.5 Million - $14.9 Million	87,748 Added 23.4%	462,748 $78.6 Million
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $42.6 Million - $50.7 Million	315,000 Added 525.0%	375,000 $59.2 Million
Q1 2021 May 17, 2021	SELL	$137.51 - $190.8 $8.25 Million - $11.4 Million	-60,000 Reduced 50.0%	60,000 $8.33 Million
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $19.8 Million - $25.4 Million	120,000 New	120,000 $21 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Polar Capital Holdings PLC with notifications on news.